ES-62 protects against collagen-induced arthritis by resetting interleukin-22 toward resolution of inflammation in the joints.
OBJECTIVE
The parasitic worm-derived immunomodulator ES-62 protects against disease in the mouse collagen-induced arthritis (CIA) model of rheumatoid arthritis (RA) by suppressing pathogenic interleukin-17 (IL-17) responses. The Th17-associated cytokine IL-22 also appears to have a pathogenic role in autoimmune arthritis, particularly in promoting proinflammatory responses by synovial fibroblasts and osteoclastogenesis. The present study was undertaken to investigate whether the protection against joint damage afforded by ES-62 also reflects suppression of IL-22.


METHODS
The role(s) of IL-22 was assessed by investigating the effects of neutralizing anti-IL-22 antibodies and recombinant IL-22 (rIL-22) on proinflammatory cytokine production, synovial fibroblast responses, and joint damage in mice with CIA in the presence or absence of ES-62.


RESULTS
Neutralization of IL-22 during the initiation phase abrogated CIA, while administration of rIL-22 enhanced synovial fibroblast responses and exacerbated joint pathology. In contrast, after disease onset anti-IL-22 did not suppress progression, whereas administration of rIL-22 promoted resolution of inflammation. Consistent with these late antiinflammatory effects, the protection afforded by ES-62 was associated with elevated levels of IL-22 in the serum and joints that reflected a desensitization of the synovial fibroblast responses. Moreover, neutralization of IL-22 during the late effector stage of disease prevented ES-62-mediated desensitization of synovial fibroblast responses and protection against CIA.


CONCLUSIONS
IL-22 plays a dual role in CIA, being pathogenic during the initiation phase while acting to resolve inflammation and joint damage during established disease. Harnessing of the tissue repair properties of IL-22 by ES-62 highlights the potential for joint-targeted therapeutic modulation of synovial fibroblast responses and consequent protection against bone damage in RA.
University of Glasgow, Glasgow, UK.
Miguel A
MA
Pineda
David T
DT
Rodgers
Lamyaa
L
Al-Riyami
William
W
Harnett
Margaret M
MM
Harnett
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000494:pharmacology; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D015801:Helminth Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000378:metabolism*; D020381:Interleukin-17 / Q000378:metabolism; D007378:Interleukins / Q000276:immunology / Q000378:metabolism*; D007596:Joints; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D000097043:Interleukin-22
D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D015801:Helminth Proteins; D020381:Interleukin-17; D007378:Interleukins; D000097043:Interleukin-22; C435884:ES-62 protein, Acanthocheilonema viteae